

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2014

CORONADO BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction
of Incorporation)

001-35366

(Commission File Number)

20-5157386

(IRS Employer
Identification No.)

24 New England Executive Park, Burlington, MA

(Address of Principal Executive Offices)

01803

(Zip Code)

Registrant's Telephone Number, Including Area Code: **(781) 652-4500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

Attached hereto as Exhibit 99.1 and incorporated herein by reference is a presentation that Coronado Biosciences, Inc. plans to use in connection with the evaluation of strategic options, including a potential financing, for its CNDO-201 or *Trichuris suis* ova asset.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Presentation of November 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORONADO BIOSCIENCES, INC.

Date: November 6, 2014

/s/ Lucy Lu

Name: Lucy Lu, M.D.

Title: Executive Vice President and
Chief Financial Officer

Altamira Bio, Inc.



Formerly TSO Development Corp.

A wholly owned subsidiary of Coronado Biosciences

November 2014

Forward-Looking Statements


Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are risks relating to: our growth strategy; results of research and development activities; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to update or revise any statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances after the date of this presentation.

Altamira's Mission

Altamira Bio, Inc. is a biotechnology company dedicated to developing *Trichuris suis* Ova (TSO), a novel immune modulator, for pediatric immune-mediated conditions with autism being the lead indication

Immune-mediated Disease Prevalence versus Helminths Exposure

Immune-mediated diseases more common in developed world




Helminths exposure more common in the developing world



■ High ■ Moderate ■ Low

Hygiene Hypothesis Science

Helminth exposure encourages immune regulation



About Us

Science Focus

- » Treat immune-mediated diseases based on the science of the "Hygiene Hypothesis"

Patient Focus

- » Pediatric immune-mediated conditions with autism being the lead indication

Disease Focus

- » Autism Spectrum Disorder (ASD)
- » Atopic Dermatitis (AD)
- » Celiac Disease

Proprietary Position

- » Only helminthic therapy in clinical trials

Leadership

- » Experienced management team and board of directors

Deep Knowledge of the Biotech World

Lucy Lu, MD

- » EVP and CFO of Coronado Biosciences since 2012
- » Therapeutic lead of the Autism program at Coronado
- » Former Senior Analyst at Citi Investment Research
- » Over 10 years of biotech equity research experience

George Avgerinos, PhD

- » SVP of biologics manufacturing at Coronado
- » Former Divisional VP, Global Process and Manufacturing Sciences, Abbvie
- » Over 30 years experience in biopharmaceutical process development including Humira™ process and manufacturing

**Lindsay Rosenwald,
MD**


- » Chairman and CEO of Coronado Biosciences
- » Prolific and successful investor in the life sciences industry for over 20 years previously as Chairman of Paramount BioCapital, Inc.
- » Co-Portfolio Manager and Partner of Opus Point Partners

What is TSO (*Trichuris suis ova*)?

Biologic comprising the microscopic eggs of the porcine whipworm

CHARACTERISTICS

- » Oral administration with no odor or taste
- » No systemic phase and no direct transmission
- » Transient exposure in humans
- » Non-human parasite and cannot multiply in human host



TSO History

What did we learn from the Crohn's disease experience?

Phase II Data
4Q2013



Crohn's disease

Result	Two Phase 2 studies failed
Decision	Investment in Crohn's was discontinued due to competitive landscape
Safety Database	500 patients
Signal of activity/effect	<ul style="list-style-type: none">» Subset of patients with higher disease activity had an improvement» Biological response on biomarkers showed a dose-dependent trend

Moving Forward

Shift focus to immune-mediated diseases in children

Phase II Data
4Q2013

~~Crohn's Disease~~

Autism (ASD) Trial
Started May 2014

- » Affects 1 in 68 children
- » Costs society \$236 billion per year
- » **No FDA approved medicine for core symptoms**

Atopic Dermatitis
(AD) Pilot Trial to
start in 2015

- » Affects 10.7% of children
- » Current therapies have undesirable side effects
- » **Large unmet need for long-term treatment of pediatric patients**

Celiac Disease
Pilot Trial to start in
2015

- » 1% of the US population
- » In past 35 years prevalence doubled every 15 years
- » **No FDA approved therapy**


altamira

Autism Spectrum Disorder (ASD)

Most significant unmet medical need

Description	<p>A complex neurodevelopmental disorder of early childhood onset characterized by deficits in social communication and restricted interests and repetitive behaviors</p> <ul style="list-style-type: none">» Many patients also have difficult behaviors such as hyperactivity, impulsivity, aggression and self-injury
Treatment	<p>Antipsychotics approved for irritability, but with serious side effects</p> <ul style="list-style-type: none">» No drugs approved for core symptoms
Competitive Landscape	<p>Lack of drug-able targets creates high barrier for entry</p> <ul style="list-style-type: none">» Minimal pipeline suggests little competition for years

Is Autism an Immune Mediated Disease?




**Publications available*

PIO
altamira

TSO for Pediatric Autism

A multi-center, randomized, double-blind, placebo-controlled, crossover study designed to evaluate the safety and efficacy of TSO in pediatric ASD patients

Initiated	May 2014
Number of Subjects	20 in the age range of 5 to 17*
Primary Endpoint	Aberrant Behavior Checklist – Irritability subscale (ABC-I)
Secondary Endpoint	Children’s Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders (CYBOCS-PDD)



**Number of patients will increase to sufficient size for efficacy detection upon successful financing*



How do we maximize efficacy signal detection in the ASD trial?

In-depth understanding of critical success factors in ASD trials

Potential Hurdle	Our Mitigation Strategies
Placebo response	<ul style="list-style-type: none">» Select experienced sites and conduct ongoing training» Enroll patients with behavior issues
Rater variability	<ul style="list-style-type: none">» Require same caretaker and rater for assessments» Include additional monitoring
Heterogeneous patient population	<ul style="list-style-type: none">» Select patients with likely immune dysregulation<ul style="list-style-type: none">» History of macrocephaly, OR» History of chronic GI issues, OR» Diagnosis of maternal/patient immune-mediated diseases

Atopic Dermatitis (AD)

Large unmet need in long-term treatment of pediatric patients

Description	A chronic relapsing, inflammatory, pruritic disease of the skin resulted from a combination of skin barrier dysfunction and immunodeviation.
Population	Commonly appears in infancy and persists into adulthood
Treatment	» Topical steroids and Calcineurin inhibitors » Systemic immunosuppressants
Status	Designing a proof-of-concept study to start in 2015

Celiac Disease

Objective histological and serological endpoints

Description	An autoimmune disorder of the small intestine triggered by dietary gluten, a form of protein found in some grains
Population	Children to adults
Treatment	Gluten avoidance (Difficult for school-aged children and adolescents)
Status	Designing a proof-of-concept study to start in 2015


The Future

A company focused on pediatric immune-mediated diseases

Autism (ASD) Study
Started May 2014

Atopic Dermatitis
Pilot Trial to start in
2015

Celiac Disease
Pilot Trial to
start in 2015



- » The only helminthic therapy in clinical development
- » **Focused** on large markets with unmet need
- » **Experienced** management and board of directors

Altamira Bio, Inc.

BIO
altamira

Formerly TSO Development Corp.

A wholly owned subsidiary of Coronado Biosciences

THANK YOU!!!
